STRO - Sutro Biopharma Short-Term Debt to Capital

Symbol and logo of brand Sutro Bio (STRO)

Sutro Biopharma, Inc. (STRO) is an innovator in the development of ultra-precise oncology drugs thanks to its unique cell-free synthesis system. High confidence among scientists is driven by the brand's ability to create less toxic therapy methods. The company's scientific potential is supported by partnership payments, as a stable cash flow is absent. This daily price chart on GURU.Markets shows the 0.00 metric, highlighting the business's dependence on research success.

Current Liabilities to Capital: Sutro Bio (STRO) for 07/04/2022 - 10/30/2026

Summary analytical data breakdowns for sutrobio.com (STRO)

- stock value and consensus price forecast:
Price Chart Sutro Bio|STRO - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Sutro Biopharma Inc.|STRO - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Sutro Biopharma|STRO - Total Stockholders' Equity|Market Value to Book Value Ratio sutrobio.com|STRO - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Sutro Biopharma, Inc.|STRO - Long-Term Liabilities to Capital|Short-Term Debt to Capital Sutro Biopharma|STRO - Company Total Indebtedness|Debt to Book Value Sutro Biopharma Inc.|STRO - Long-Term Debt|Company Current Liabilities Sutro Biopharma|Quick Ratio sutrobio.com
- company profitability and valuation multiples indicators:
STRO - Net Financial Result
Initial company analysis:Sutro Bio STRO
Signature product of sutrobio.com

Analyzing the short-term debt dynamics of Sutro Biopharma, Inc. (STRO) allows for an assessment of the financial stability of this developer of precision antibody-drug conjugates for cancer therapy. This ratio correlates liabilities with a maturity of up to one year against total equity, enabling investors to filter out market noise and determine the company's actual reliance on short-term loans, which is critical for assessing default risk within the capital-intensive biotechnology sector.

Competitors of Sutro Biopharma, Inc. (STRO)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|INKT: Short-Term Debt to Capital|HOWL - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Immix Biopharma Inc.|Short-Term Debt to Equity Ratio alxoncology.com (ALXO)|Short-Term Debt to Equity Cue Biopharma (CUE)|Short-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital MAIA Biotech MAIA|LIMN - Short-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Short-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity